ReviewDiscover nano2026
Overcoming chemotherapy resistance in diffuse large B-cell lymphoma using multifunctional nanocarriers: current advances and clinical challenges.
Review in Discover nano, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chemoresistance is a primary challenge in diffuse large B-cell lymphoma (DLBCL) treatment. The review is developed to explore the potential of the nanocarrier strategy to minimize resistance in DLBCL treatment. The application of nanocarriers offers promising solutions to increase the drug delivery, avoid resistance, and minimize off-target delivery. Therapeutic strategies of nanocarriers with targeted delivery, gene-based therapies, and combination therapies are explained in the review. This review further evaluates the CXCR4 and Transferrin Receptor 1 (TFR1) efficacy through highly functional nanocarriers that control resistance in the drug pathways. Moreover, it is found that microRNA (miRNA) and small interfering RNA (siRNA) delivery through nanocarriers is beneficial to reduce the chemoresistance and resensitise the DLBCL cells. Furthermore, the review included the significance of multifunctional nanocarriers that combine drug delivery with a stimuli-responsive system and gene regulation that further releases therapeutics in a selective tumour environment. The treatment option is also associated with various challenges, like biological barriers, scalability, safety issues, and the specificity of targeting impacts on the clinical adoption of these technologies. The future research is recommended to focus on the optimization of the nanocarrier design, integration of nanocarriers, and conducting clinical and pre-clinical studies using other therapeutic modalities, that can improve the treatment outcomes for DLBCL patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.